Switzerland-based AC Immune SA is expecting readouts this year from five clinical-stage products for neurological diseases which will give the first indication of how its multi-compound approach for treating Alzheimer’s disease is faring. Two of the trials are testing a vaccine targeting amyloid-beta in Alzheimer’s disease and Down syndrome. The other three include a vaccine, an antibody and a small molecule drug each directed against tau in Alzheimer’s disease. Tau is a protein found in neurons which, when it has become dysfunctional, drives cognitive decline and memory loss.
